Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01521533
Other study ID # SNOXA12C301
Secondary ID 2011-004651-40
Status Completed
Phase Phase 2
First received January 26, 2012
Last updated October 5, 2015
Start date March 2012
Est. completion date September 2015

Study information

Verified date October 2015
Source NOXXON Pharma AG
Contact n/a
Is FDA regulated No
Health authority Italy: The Italian Medicines AgencyAustria: Austrian Medicines and Medical Devices AgencyFrance: Agence Nationale de Sécurité du Médicament et des produits de santéGermany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of NOX A12 alone and in combination with a background therapy of bortezomib and dexamethasone (VD) chemotherapy in previously treated patients with multiple myeloma (MM).


Description:

Malignant plasma cells express high levels of CXCR4 chemokine receptors, which cause cell migration and adhesion to stromal cells secreting the CXCR4 ligand, CXCL12 (SDF-1). NOX A12 is a specific CXCL12 antagonist and may improve chemotherapy by disrupting CXCR4-CXCL12 interactions, thereby mobilizing plasma cells from protective tissue microenvironments to the blood. Furthermore, SDF-1 inhibition may alter the activation status of plasma cells, thereby triggering apoptosis or sensitization of plasma cells towards chemotherapy.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date September 2015
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male or female, aged = 18 years.

2. Diagnosis of relapsed multiple myeloma for which bortezomib/dexamethasone would be given as standard of care.

3. Bortezomib-naïve or bortezomib-sensitive patient (i.e. best response of PR or better, sustained for at least 6 months), who did not receive bortezomib during the last line of therapy for MM prior to this study.

4. Progressive disease according to International Myeloma Working Group criteria.

5. Pre-study WHO Performance Status = 2 and modified CIRS score of less than 7.

6. Signed and dated, written informed consent.

7. Men and women of reproductive potential must agree to follow accepted contraception methods during treatment and for 3 months after completion of treatment.

8. Acceptable liver function: Bilirubin = 1.5 x upper limit of normal (ULN).

9. Acceptable hematology and hemostasis status: Platelet count = 75 x 109/L, ANC > 0.75x109/L.

10. Acceptable renal function: Serum creatinine =1.5 ULN and/or calculated creatinine clearance = 50 mL/min (calculated according to Cockroft & Gault formula).

11. No clinically significant abnormalities of liver volume, liver hemodynamics or elasticity, measured by abdominal ultrasound.

Exclusion Criteria:

1. The patient has a history of, or is clinically suspicious for, cancer-related Central Nervous System disease.

2. Prior allogeneic stem cell transplant (alloSCT) or patients who are considered to be candidates for alloSCT as assessed by their treating physician.

3. Patient has a history of other active malignancies within 3 years prior to study entry, with the exception of: adequately treated in situ carcinoma of the cervix uteri; basal or squamous cell carcinoma of the skin; in situ carcinoma of the bladder; previous malignancy confined and surgically resected with curative intent.

4. The patient exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: uncontrolled systemic infection (viral, bacterial, or fungal); diagnosis of fever and neutropenia within 1 week prior to study drug administration.

5. Female patient is pregnant or breast-feeding.

6. Known infection with HIV, active Hepatitis B or Hepatitis C.

7. The patient has a history of prior toxicity from bortezomib or dexamethasone that resulted in permanent discontinuation of respective treatments.

8. Clinical evidence of a current significant (grade 2 or higher) or progressive neuropathy.

9. Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to study drug administration.

10. Uncontrolled hypertension (defined as systolic blood pressure [BP] > 160 mm Hg or diastolic BP > 100 mm Hg).

11. Myocardial infarction or unstable angina within the past 6 months prior to study drug administration. Heart failure of New York Heart Association functional Class III or IV prior to study drug administration.

12. Evidence of bleeding diathesis (greater than normal risk of bleeding) or coagulopathy (in the absence of therapeutic anticoagulation).

13. Systemic illnesses or other severe concurrent disease or alcoholism, which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and efficacy of the investigational treatments.

14. Known or suspected of not being able to comply with the trial protocol.

15. Having been previously enrolled in this clinical trial.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
NOX-A12
Pilot Group (NOX A12 single agent, and combined with VD): 3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose. Expansion Group (NOX A12 in combination with VD): Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group.

Locations

Country Name City State
Austria University Hospital Salzburg, Department of Medicine III, Center of Oncology and Hematology Salzburg
Austria Wilhelminenspital, Department of Medicine I, Center of Oncology and Hematology Vienna
France Hôpital Huriez, Centre Hospitalier Régional Universitaire de Lille Lille
France Hôpital Saint Antoine - Service des maladies du sang et de thérapie cellulaire Paris
Germany University Hospital Freiburg, Medizinische Universitätsklinik, Innere Medizin I, Haematologie und Onkologie Freiburg
Germany University Hospital Münster, Medizinische Klinik und Poliklinik A Münster
Germany University Hospital Ulm, Zentrum für Innere Medizin, Ulm
Italy University Hospital San Martino, Department of Hematology and Oncology Genova
Italy Niguarda Ca'Granda Hospital, Department of Hematology Milano
Italy Sapienza University of Rome, Department of Hematology Rome

Sponsors (1)

Lead Sponsor Collaborator
NOXXON Pharma AG

Countries where clinical trial is conducted

Austria,  France,  Germany,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate (ORR = best response at least partial response (PR)) Assessment of the overall tumor response after cycle 4 and 8 will be the primary efficacy endpoint. The recommendations for the uniform reporting of clinical trials as published by the International Myeloma Workshop Consensus Panel 1 in 2011 will be applied. 6 months No
Primary Safety and tolerability of NOX A12 alone and in combination with VD The safety evaluation will be based on the following assessments:
Adverse events
Vital signs
12 lead ECGs
Laboratory parameters
Abdominal ultrasound
Immunogenicity
18 months Yes
Secondary Effect of NOX A12 alone and combined with VD on the mobilization of peripheral blood CD34+ cells, plasma cells and myeloma cells 6 months No
Secondary Additional response criteria such as Minor Response (MR), immunophenotypic Complete Response and molecular Complete Response 6 months No
Secondary Time to event endpoints such as Progression Free Survival (PFS), Time To Progression (TTP) and Duration Of Response (DOR) following treatment with NOX A12 in combination with VD 18 months No
Secondary Plasma concentration of SDF-1 after treatment with NOX-A12 alone (pilot group only) and in combination with VD 6 months No
Secondary Pharmacokinetics of NOX A12 alone (pilot group only) and combined with VD 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1